Immunome, Inc. (NASDAQ:IMNM) Receives $23.33 Average Price Target from Analysts

Immunome, Inc. (NASDAQ:IMNM - Get Free Report) has been given an average recommendation of "Buy" by the six ratings firms that are presently covering the company, Marketbeat.com reports. Six research analysts have rated the stock with a buy rating. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $23.33.

IMNM has been the subject of a number of research analyst reports. Wall Street Zen raised shares of Immunome from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Lake Street Capital started coverage on shares of Immunome in a report on Wednesday, April 2nd. They issued a "buy" rating and a $23.00 target price on the stock. Stephens reiterated an "overweight" rating and issued a $30.00 target price on shares of Immunome in a report on Thursday, March 20th. Guggenheim dropped their target price on shares of Immunome from $35.00 to $25.00 and set a "buy" rating on the stock in a report on Thursday, March 20th. Finally, Wedbush reiterated an "outperform" rating and issued a $21.00 target price (down from $33.00) on shares of Immunome in a report on Tuesday, May 13th.

Insider Activity

In other news, Director Jean Jacques Bienaime purchased 5,000 shares of the business's stock in a transaction dated Tuesday, June 3rd. The shares were acquired at an average price of $9.38 per share, for a total transaction of $46,900.00. Following the completion of the acquisition, the director directly owned 36,415 shares of the company's stock, valued at $341,572.70. The trade was a 15.92% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 8.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Immunome

A number of large investors have recently made changes to their positions in the company. Wealth Enhancement Advisory Services LLC raised its holdings in shares of Immunome by 3.2% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 53,187 shares of the company's stock valued at $470,000 after acquiring an additional 1,643 shares during the period. Voya Investment Management LLC raised its holdings in shares of Immunome by 21.2% during the first quarter. Voya Investment Management LLC now owns 18,905 shares of the company's stock valued at $127,000 after acquiring an additional 3,305 shares during the period. Rhumbline Advisers raised its holdings in shares of Immunome by 30.4% during the first quarter. Rhumbline Advisers now owns 88,888 shares of the company's stock valued at $598,000 after acquiring an additional 20,721 shares during the period. Woodline Partners LP raised its holdings in shares of Immunome by 69.0% during the first quarter. Woodline Partners LP now owns 1,657,729 shares of the company's stock valued at $11,157,000 after acquiring an additional 676,804 shares during the period. Finally, Zimmer Partners LP acquired a new stake in shares of Immunome during the first quarter valued at approximately $673,000. Institutional investors and hedge funds own 44.58% of the company's stock.

Immunome Stock Performance

Shares of NASDAQ:IMNM traded up $0.78 during trading on Monday, reaching $10.45. The company had a trading volume of 1,250,355 shares, compared to its average volume of 910,264. The firm's fifty day moving average is $8.77 and its 200 day moving average is $8.89. The firm has a market capitalization of $909.25 million, a PE ratio of -3.29 and a beta of 1.92. Immunome has a twelve month low of $5.15 and a twelve month high of $16.81.

Immunome (NASDAQ:IMNM - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported ($0.52) earnings per share for the quarter, topping analysts' consensus estimates of ($0.66) by $0.14. The company had revenue of $2.93 million during the quarter, compared to analyst estimates of $0.46 million. Immunome had a negative net margin of 1,875.21% and a negative return on equity of 71.65%. Equities analysts predict that Immunome will post -2.21 earnings per share for the current fiscal year.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.